Barely Significant
← all excerpts

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy.

Clin Ophthalmol · 2018 · PMC6304237 · PMID 30587912

Europe PMCDOI
1
hedged sentence
0.0840
closest p · 1.7× alpha
0.0840
boldest claim

The sentences

not significantly significantP =0.084so close (0.05 < p ≤ 0.1)
The percentage of patients with ≥25% reduction in IOP from baseline was higher in the LBN group as compared to the timolol group (31.0% vs 18.5%, P =0.007) and a higher percentage of subjects in the LBN group than in the timolol group had their IOP reduced to ≤ 18 mm Hg (17.7% vs 11.1%) though this was not significantly significant ( P =0.084). 19 In a pooled analysis of the APOLLO and LUNAR studies, LBN 0.024% provided greater IOP lowering compared to timolol 0.5% at 3 months of therapy and remained effective during the open-label extension phases of both studies.

also in 164 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.